摘要
目的:观察131I-17-丙烯胺基-17-脱甲基格尔德霉素(131I-17-AAG)治疗卵巢癌移植瘤模型的骨髓及肝脏毒副作用。方法:40只BALB/c裸鼠,制成荷卵巢癌模型后,按完全随机原则分为两组,一组(治疗组):20只,3mCi131I-17-AAG尾静脉注射。二组(对照组):20只,为未经治疗的荷瘤裸鼠。一、二组荷瘤裸鼠均于1周及二周眶静脉采血,进行血常规(白细胞、红细胞、血红蛋白、血小板)及酶学(谷草转氨酶、谷丙转氨酶、碱性磷酸酶、谷氨酰转移酶)检查。数据用SPSS14.0进行统计学分析。结果:白细胞、红细胞和血红蛋白2周时无显著差异(P>0.05),血小板2周有显著差异(P<0.05)。谷丙转氨酶、谷草转氨酶2周有显著差异(P<0.05),碱性磷酸酶、谷氨酰转移酶2周时无显著差异(P>0.05)。结论:131I-17-AAG对骨髓造血干细胞及肝功能各项指标有不同程度的影响,且随时间逐步得到恢复。
Objective To investigate the toixc side effect on bone marrow and hepatic function of ^131Ⅰ- 17 - allylamino - 17 - demethoxy geldanamycin （ ^131Ⅰ- 17 AAG） treatment for ovarian - cancer - bearing nude mice models. Methods Ovarian - cancer - bearing nude mice models （n =40） were prepared with cancer cell inoculation. ^131Ⅰ labelled 17 AAG originally prepared in this laboratory was used intravenously for treatment at a single dose of 3 mCi in 20 models and the remain 20 models were used as controls. Runfine bllod examination （ CBC, Hgb, platalet） and liver function test （ ALT, AST, ALP and r - GT） were performed in these models at lwk and 2wk after treatment. Results CBC and Hgb in the treated models were not much different from those in controls at 2wk with the exception of a higher platalet count （ P 〈 0.001 ）. ALT and AST levels were significantly higher in the treated models than those in untreated ones at 2wk （ P 〈 0.05 ）, while ALP and rGT levels in the treated models were not significantly different from those in controls at 2wk （P 〉 0.05）. Conclusion Toxic side - effect of ^131 Ⅰ - 17 - AAG treatment on hematologyical and nepatic function in the models was rather mild and there was a tendency toward recovery at 2wk after treatment.
出处
《放射免疫学杂志》
CAS
2007年第6期542-544,共3页
Journal of Radioimmanology
基金
国家自然科学基金资助项目(批准号:30470500)
江苏省科技厅社会发展指令性计划(编号:BS2004020)
扬州市科技局社会发展指令性计划(编号:YZ2004047)
